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Abstract
Objectives: To investigate the prevalence and distribu-
tion of comorbidity and its association with perioperative
complications in patients undergoing radical prostatec-
tomy (RPE). Methods: In 431 unselected RPE patients,
the American Society of Anesthesiologists Physical Sta-
tus classification (ASA-PS), the New York Heart Associa-
tion classification of cardiac insufficiency (NYHA), the
classification of angina pectoris of the Canadian Cardio-
vascular Society (CCS), height, weight, the body mass
index (BMI), and the number of concomitant diseases
(NCD) were assessed and related to perioperative cardio-
vascular complications. Results: In RPE patients less
than 70 years old, comorbidity rose nearly continuously
with increasing age. However, after reaching an age of
70 years, the proportion of NYHA-0 patients increased
(60–64 years, 86%; 65–69 years, 85%; 670 years, 87%).
Furthermore, the severe comorbidities decreased in pa-
tients selected for RPE aged 70 or more years. There was
a nonsignificant trend towards higher comorbidity in
patients with perioperative cardiovascular complica-
tions. Conclusions: These data suggest that documenta-
tion of the distribution of ASA-PS, CCS, NYHA and of
concomitant diseases might be helpful to characterize
the general health status and the degree of selection of
prostate cancer treatment populations especially in se-
ries with a high portion of patients aged 70 or more
years. Concerning perioperative complications, the indi-
vidual predictive value of comorbidity seems to be poor
in the radical prostatectomy setting.
Copyright © 2001 S. Karger AG, Basel
Introduction
Traditionally, an age of 70 years has been considered
as a limit for patients to be candidates for radical prosta-
tectomy [1, 2]. During the last years, however, the proce-
dure has become increasingly popular in elderly patients.
In a contemporary series [3], more than half of the
patients were 70 years old or older. Although comorbidity
considerably influences survival [4], few data are avail-
able on the prevalence of concomitant diseases in prostate
cancer patients. Some studies dealt with comorbidity in
screening populations [5], unselected newly diagnosed
prostate cancer patients [6], and with the influence of
comorbidity on the life expectancy of conservatively
284 Urol Int 2001;67:283–288 Froehner/Litz/Manseck/Hakenberg/Leike/
Albrecht/Wirth
Fig. 1. Distribution of ASA-PS in patients
undergoing RPE in the 5 age groups and
among patients without and with cardiovas-
cular complications. After a fairly contin-
uous increase, the portion of ASA-PS 3 pa-
tients decreased after reaching an age of 70
or more years. ASA-PS 3 seemed to be slight-
ly overrepresented in patients with cardio-
vascular complications.
treated prostate cancer patients [4]. However, only few
series with comorbidity information in patients undergo-
ing radical prostatectomy have been reported [7, 8]. To
our knowledge, only one study investigated the relation-
ship between comorbidity and perioperative complica-
tions in the radical prostatectomy setting [8]. In this
study, we assessed the prevalence and distribution of con-
comitant diseases and perioperative complications in 431
radical prostatectomy patients.
Materials and Methods
The records of 433 unselected patients (mean age 63.5, range 45–
75 years) who underwent radical prostatectomy at a single center in
the years 1992–1999 were retrospectively reviewed. Patients were
enrolled into this study according to their availability in a database
designed to study different anesthetic procedures [9]. Two patients
were excluded from analysis because of incomplete data. Data con-
cerning comorbidity classifications (American Society of Anesthesi-
ologists Physical Status classification (ASA-PS, six categories 1–6);
New York Heart Association classification of cardiac insufficiency
(NYHA, five categories 0–4), and the classification of angina pectoris
of the Canadian Cardiovascular Society (CCS, four categories 1–4)),
height, weight, and body mass index (BMI) were taken from the anes-
thesiologic premedication records and were checked by chart review
and (in the case of CCS) by review of the preoperative electrocardio-
gram. Six concomitant diseases were recorded from both the preme-
dication form and the patient chart: cardiac insufficiency (NYHA
11), hypertension, diabetes, history of thromboembolism, chronic
obstructive and restrictive pulmonary disease. The number of con-
comitant diseases (NCD) was calculated for each patient from these
data and compared between patients with ASA-PS 1, 2, and 3,
respectively, using Student’s t test. Patients aged !70 years were
compared with those aged 670 years by comorbidity (ASA-PS,
NYHA, CCS, NCD), height, weight, and BMI with ¯2 or Student’s t
test. Two general types of perioperative complications were discrimi-
nated: cardiovascular complications (any perioperative death, ve-
nous thrombosis, thromboembolism, myocardial infarction, pulmo-
nary edema), and miscellaneous complications (such as wound infec-
tion, diarrhea, insignificant cardiac arrhythmia, pneumonia, pelvic
lymphoceles). The relationship between comorbidity and cardiovas-
cular complications was investigated by univariate (¯2 or the Stu-
dent’s t test) and multivariate (logistic regression) analysis.
Results
Whereas the BMI decreased, all investigated comor-
bidities (ASA-PS, range 1–3; NYHA, range 0–3; CCS,
range 0–3; NCD, range 0–4) rose nearly continuously
with increasing age in patients less than 70 years old
(fig. 1–4). However, after reaching the age of 70 years, the
prevalence of cardiac insufficiency (NYHA) fell slightly,
and the proportion of NYHA-0 patients increased (fig. 2).
Furthermore, the proportion of severe comorbidities
(ASA-PS 3, NCD 11) decreased (fig. 1, 4). The portion of
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Fig. 2. Distribution of cardiac insufficiency
(NYHA) in patients undergoing RPE in the
5 age groups and among patients without
and with cardiovascular complications. Af-
ter a fairly continuous decrease, the portion
of NYHA 0 patients increased after reaching
an age of 70 or more years. Cardiac insuffi-
ciency seemed to be slightly overrepresented
in patients with cardiovascular complica-
tions.
Fig. 3. Distribution of angina pectoris (CCS)
in patients undergoing RPE in the 5 age
groups and among patients without and with
cardiovascular complications. There was a
continuous, possibly slightly progressive in-
crease in the prevalence of angina pectoris
over all 5 age groups. Angina pectoris
seemed to be slightly overrepresented in pa-
tients with cardiovascular complications.
patients aged 70 or more years (overall 14%) increased
from 10% (NCD = 0) to 18% (NCD = 1), but fell to 17%
(NCD = 2) and 6% in patients with NCD = 3–4. There
was a tendency towards higher comorbidity in patients
aged 70 or more years compared with younger men; how-
ever, only the categories ASA-PS (p = 0.049) and CCS (p =
0.0029) reached statistical significance. Mean height (172
versus 174 cm, p = 0.049) and weight (77 versus 80 kg, p =
0.049) were significantly lower in patients aged 70 or
more years compared with younger patients. Concerning
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Fig. 4. Distribution of the number of con-
comitant diseases (NCD) in patients un-
dergoing RPE in the 5 age groups and among
patients without and with cardiovascular
complications. In patients aged less than 70
years, the prevalence of concomitant dis-
eases rose fairly continuously with age.
Beyond this limit, however, the portion of
patients with 2 or more concomitant dis-
eases decreased. Concomitant diseases
seemed to be slightly overrepresented in pa-
tients with cardiovascular complications.
Fig. 5. Distribution of the 5 age groups among patients without and
with cardiovascular complications. Patients aged 65 or more years
seemed to be slightly underrepresented in the group with cardiovas-
cular complications.
BMI, statistical significance was not reached (25.8 versus
26.5 kg/m2, p = 0.135). The NCD differed significantly
between patients with ASA-PS 1 (n = 68, mean NCD =
0.00, p ! 0.0001), ASA-PS 2 (n = 324, mean NCD = 0.75,
p ! 0.0001) and ASA-PS 3 (n = 39, mean NCD = 1.90, p !
0.0001).
Perioperative complications were recorded in 98 pa-
tients. 15 events were considered cardiovascular compli-
cations: 3 deaths within 30 days postoperatively (1 imme-
diately postoperatively, 2 shortly after discharge from the
hospital); one myocardial infarction; 3 pulmonary embo-
lisms; 7 venous thromboses, and 1 pulmonary edema.
Taking all recorded complications together, the distribu-
tion of age and comorbidities was nearly the same be-
tween patients with and without complications. Focus-
sing on cardiovascular complications, however, there was
a trend towards higher comorbidity (ASA-PS, NYHA,
CCS, NCD) in patients with such complications (fig. 1–
4). However neither univariate nor multivariate analysis
revealed statistically significant differences. There was no
significant age difference between patients with (mean
age 62.2 years) and without cardiovascular complications
(mean age 63.5 years). Considering the age distribution,
there seemed to be a (nonsignificant) trend towards un-
derrepresentation of elderly patients in the group with
cardiovascular complications (fig. 5).
!54
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Table 1. Age-related height, weight, BMI, and distribution of concomitant diseases among 431 radical prostatectomy patients
Age group
years
n Mean
NCD
CI
(NYHA
2 or 3), %
Hyper-
tension
%
Diabetes
%
History of
thrombo-
embolism, %
COPD
%
RPD
%
Mean body
weight, kg
Mean body
height, cm
Mean
BMI
kg/m2
35 0.46 6 23 6 0 9 3 82 175 26.8
55–59 73 0.63 7 39 10 0 7 1 82 175 26.7
60–64 131 0.66 8 43 9 1 5 0 80 174 26.5
65–69 132 0.89 9 52 14 6 8 0 79 174 26.3
70+ 60 0.87 10 52 13 2 8 2 77 172 25.8
Overall 431 0.74 8 44 11 2 7 1 80 174 26.4
CI = Cardiac insufficiency; COPD = chronic obstructive pulmonary disease; RPD = restrictive pulmonary disease.
Discussion
Since prostate cancer is mostly a slowly progressing
disease of old age, comorbidity and patient selection have
significant implications for the interpretation of clinical
trials [4, 10]. Nevertheless, only few data are available on
the prevalence of comorbidities in prostate cancer pa-
tients [6]. Data from studies addressing comorbidity in
prostate cancer vary in the way data were collected and in
the choice of conditions recorded. Post et al. [6] reported
comorbidity data from newly diagnosed prostate cancer
patients from the southern Netherlands. Compared with
their data, there was a lower portion of patients without
any concomitant disease in all age groups in our sample.
However, the authors [6] did not record hypertension as a
comorbidity, which accounted for more than a half of the
concomitant diseases in our study group (table 1). When
hypertension is excluded, the subgroup without comor-
bidity was nearly the same in patients aged less than 60
years as in the cited study [6], whereas in men aged more
than 60 years there was an even lower comorbidity in our
study. It is, however, unclear whether this difference does
really exist or whether it may be attributed to differences
in study design. Compared to elderly male participants of
the Canada Health Survey (questionnaire-based, mean
age 66.6 years) [5], in our series the proportion of men
without any comorbidies was equal in patients aged 60–
69 years and lower in those aged 70 or more years. This
possibly reflects the selection in favor of good risks in this
subgroup. Considering radical prostatectomy series with
available comorbidity data, in a study by Koch and Smith
[11] (n = 109, mean age 62 years) the prevalence of dia-
betes was equal to that in our series (11% [11]), whereas
hypertension (26 [11] versus 44%) and chronic obstruc-
tive pulmonary disease (1 [11] versus 7%) were less fre-
quent. Among men aged 60 or more years in the Canada
Health Survey [5], emphysema/chronic bronchitis (9.3%)
and hypertension (36.6%) were similarily as common as
in our study (fig. 5). This suggests an elimination by selec-
tion or an underreporting of these two conditions in the
cited series [11]. In another study [7], comorbidity infor-
mation was derived from hospital records of 138 radical
prostatectomy patients (median age 64.5 years) and of
138 patients (median age 69.0 years) undergoing radio-
therapy. Compared with our series, chronic pulmonary
disease and diabetes were less common in the radical
prostatectomy group; however, these diseases were con-
siderably overrepresented in the radiotherapy group, ob-
viously due to a selection effect. Combining both groups,
the frequency of both conditions was nearly equal in the
(somewhat elderly) population of Fowler et al. [7] and in
our series (diabetes 12 [7] versus 11%, chronic pulmonary
disease 8 [7] versus 8%).
Three groups provided ASA-PS classification data for
patients undergoing radical prostatectomy [8, 11, 12]. The
age distribution in these series was almost the same as in
our study. Concerning the distribution of patients with
ASA-PS 3, our data (fig. 1) are similar to those reported by
Dillioglugil et al. [8] who also found a fairly linear increase
of the percentage of patients with ASA-PS 3 below an age
of 70 years followed by a decrease in the patients aged 70
or more years. The proportion of ASA-PS 3 patients was,
however, higher in all three studies cited (16% [8], 23%
[11], 27.8% [12]), compared with our series (9%). It is not
clear whether these conflicting results were really caused
by differences between the study populations or whether
they were due to different classification standards. In
order to achieve comparability, it seems to be necessary to
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collect more detailed and objective information on special
health aspects such as the prevalence of other diseases
(the mean NCD differed highly significantly between
the ASA-PS classifications in our series) and heart func-
tion (NYHA, CCS), especially since these comorbidities
seemed to represent selection criteria in our series. It was
conspicuous that, beyond the traditional radical prosta-
tectomy age limit of 70 years, the proportion of NYHA-0
patients increased after a fairly continuous decrease up to
this point (fig. 2). Furthermore, patients over 70 years old
were underrepresented on the subgroup with severe co-
morbidity (NCD 11; fig. 4). ASA-PS, NYHA and NCD
were obviously selection criteria in patients over 70 years
old. The decreasing BMI reflects the tendency of body
weight to decrease after an age of 60 years [13] and should
not be attributed to selection.
In contrast to the study by Dillioglugil et al. [8], which
found a significant association between comorbidity
(ASA-PS) and major perioperative complications, statisti-
cal significance was not reached in our study. It is, how-
ever, likely that such a relationship exists, since there
seemed to be a trend towards higher comorbidities in
all four classifications assessed (ASA-PS, NYHA, CCS,
NCD) in patients with cardiovascular complication
(fig. 1–4). In our series, 9% of patients were classified as
ASA-PS 3 (16% in the series of Dillioglugil et al. [8]), pos-
sibly reflecting a more favorable risk profile in our series
requiring a higher number of patients to identify differ-
ences. Furthermore, Dillioglugil et al. [8] used a meticu-
lous severity score for adverse events which we consid-
ered not applicable to our retrospective series.
In conclusion, patients aged 70 or more years have
been shown to be likely to have undergone selection by
exclusion of severe comorbidities (ASA-PS3 or NCD 11 =
exclusion from radical prostatectomy) and selection of
patients with excellent heart function (NYHA 0 = encour-
agement to undergo radical prostatectomy despite ad-
vanced age). In any radical prostatectomy study popula-
tions with a high portion of patients aged 70 or more
years, the additional documentation of the distribution of
concomitant diseases and of any impairment of heart
function (CCS, NYHA) might be helpful to enable com-
parability of the general health status, which is likely to
affect outcome. Despite a possible trend towards higher
comorbidity in patients with cardiovascular complica-
tions, the individual predictive value seems to be poor in
appropriately selected radical prostatectomy patients.
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